PIK3CA-mutated melanoma cells rely on cooperative signaling through mTORC1/2 for sustained proliferation.

about

PIK3CA-mutated melanoma cells rely on cooperative signaling through mTORC1/2 for sustained proliferation.

Item

http://www.wikidata.org/entity/Q46095420

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

PIK3CA-mutated melanoma cells ...... 2 for sustained proliferation.

@en

PIK3CA-mutated melanoma cells ...... 2 for sustained proliferation.

@nl

type

Item

label

PIK3CA-mutated melanoma cells ...... 2 for sustained proliferation.

@en

PIK3CA-mutated melanoma cells ...... 2 for sustained proliferation.

@nl

prefLabel

PIK3CA-mutated melanoma cells ...... 2 for sustained proliferation.

@en

PIK3CA-mutated melanoma cells ...... 2 for sustained proliferation.

@nl

P1476

PIK3CA-mutated melanoma cells ...... 2 for sustained proliferation.

@en

P2093

Bruce C Baguley

http://www.w3.org/2001/XMLSchema#string

Jillian M Silva

http://www.w3.org/2001/XMLSchema#string

Marian M Deuker

http://www.w3.org/2001/XMLSchema#string

P2860

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2

A landscape of driver mutations in melanoma

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

mTOR: from growth signal integration to cancer, diabetes and ageing

Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond

The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer

Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase

Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973)

Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation

Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.

P304

353-367

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/PCMR.12586

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Martin McMahon

P577

2017-04-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28233937

http://www.w3.org/2001/XMLSchema#string

P932

5411292

http://www.w3.org/2001/XMLSchema#string